Literature DB >> 15213603

Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases.

Robin L Parker1, Philip B Clement, David J Chercover, Thangaraja Sornarajah, C Blake Gilks.   

Abstract

Ovarian serous borderline tumors (SBTs) are characteristically associated with an indolent course. Recurrences are often delayed and usually show morphologic features of SBT or low-grade serous carcinoma. Transformation to high-grade carcinoma has rarely been documented. We report 2 cases of ovarian SBTs that recurred early as high-grade carcinomas. The first was a 50-year-old woman treated surgically and with chemotherapy for a FIGO stage 1C SBT with microinvasion, who experienced a recurrence in an axillary lymph node at 27 months. The recurrent tumor consisted of well-differentiated papillary serous tumor that resembled the primary tumor and poorly differentiated serous carcinoma. The patient died of progressive disease 43 months after her initial presentation. The second case was a 61-year-old woman treated surgically and with chemotherapy for a stage 3C micropapillary SBT with noninvasive implants. Eighteen months later, an incisional hernia was found that contained high-grade sarcomatoid-type carcinoma with microscopic foci of better differentiated tumor that resembled the primary SBT. This patient is alive with disease 24 months after her initial presentation. Whereas the malignant potential of SBTs remains controversial, the cases described herein demonstrate that SBTs can behave unpredictably and may rarely transform into high-grade carcinoma.

Entities:  

Mesh:

Year:  2004        PMID: 15213603     DOI: 10.1097/01.pgp.0000130049.19643.f6

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  11 in total

1.  Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case.

Authors:  Mahkam Tavallaee; David F Steiner; James L Zehnder; Ann K Folkins; Amer K Karam
Journal:  Int J Gynecol Pathol       Date:  2019-07       Impact factor: 2.762

Review 2.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

3.  Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.

Authors:  Rajmohan Murali; Pier Selenica; David N Brown; R Keira Cheetham; Raghu Chandramohan; Nidia L Claros; Nancy Bouvier; Donavan T Cheng; Robert A Soslow; Britta Weigelt; W Glenn McCluggage
Journal:  Histopathology       Date:  2019-01-15       Impact factor: 5.087

4.  Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.

Authors:  Michael Herman Chui; Deyin Xing; Felix Zeppernick; Zoe Q Wang; Charlotte G Hannibal; Kirsten Frederiksen; Susanne K Kjaer; Leslie Cope; Robert J Kurman; Ie-Ming Shih; Tian-Li Wang; Russell Vang
Journal:  Am J Surg Pathol       Date:  2019-11       Impact factor: 6.394

5.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

6.  KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Authors:  Yvonne T Tsang; Michael T Deavers; Charlotte C Sun; Suet-Yan Kwan; Eric Kuo; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

7.  Low-grade serous neoplasms of the ovary with transformation to high-grade carcinomas: a report of 3 cases.

Authors:  Karuna Garg; Kay J Park; Robert A Soslow
Journal:  Int J Gynecol Pathol       Date:  2012-09       Impact factor: 2.762

8.  Low-Stage High-Grade Serous Ovarian Carcinomas: Support for an Extraovarian Origin.

Authors:  Elizabeth Morency; Mario M Leitao; Robert A Soslow
Journal:  Int J Gynecol Pathol       Date:  2016-05       Impact factor: 2.762

Review 9.  Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Int J Gynecol Pathol       Date:  2008-04       Impact factor: 2.762

10.  P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.

Authors:  Dinka Sundov; Ana Caric; Ivana Mrklic; Dijana Gugic; Vesna Capkun; Irena Drmic Hofman; Branka Petric Mise; Snjezana Tomic
Journal:  Diagn Pathol       Date:  2013-02-06       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.